🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 20 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/01/2017 14,53 14,53 14,16 14,43 -0,62% 2,55% 373.500
19/01/2017 14,38 15,00 14,38 14,52 +0,69% 4,31% 531.600
18/01/2017 14,80 15,00 14,25 14,42 -1,97% 5,07% 657.700
17/01/2017 15,38 15,38 14,36 14,71 -4,91% 6,63% 1.068.500
13/01/2017 15,44 15,89 15,06 15,47 +0,72% 5,36% 559.600
12/01/2017 14,82 15,87 14,40 15,36 +1,79% 9,92% 968.500
11/01/2017 15,01 16,50 14,77 15,09 +1,07% 11,53% 2.000.200
10/01/2017 14,43 14,97 14,10 14,93 +4,48% 6,01% 1.289.300
09/01/2017 13,04 14,50 12,85 14,29 +10,35% 12,65% 1.156.400
06/01/2017 12,91 13,70 12,71 12,95 +2,13% 7,66% 965.600
05/01/2017 11,25 12,90 11,19 12,68 +7,91% 15,23% 866.600
04/01/2017 11,23 11,97 11,20 11,75 +4,63% 6,86% 1.011.200
03/01/2017 11,06 11,44 10,85 11,23 +2,93% 5,37% 435.500
30/12/2016 11,15 11,41 10,67 10,91 -2,42% 6,64% 733.400
29/12/2016 11,39 11,70 10,79 11,18 -2,19% 7,99% 935.200
28/12/2016 11,68 11,79 11,33 11,43 -2,06% 3,94% 547.600
27/12/2016 12,33 12,51 11,62 11,67 -4,81% 7,22% 872.100
23/12/2016 12,01 12,30 11,69 12,26 +4,52% 5,08% 638.900
22/12/2016 11,83 12,10 11,60 11,73 -1,18% 4,23% 355.000
21/12/2016 12,16 12,30 11,85 11,87 -3,42% 3,70% 513.200
20/12/2016 12,34 12,60 12,05 12,29 +0,41% 4,46% 499.100
19/12/2016 12,38 12,79 12,18 12,24 -1,53% 4,93% 574.400
16/12/2016 12,18 12,90 12,18 12,43 +2,30% 5,91% 866.700
15/12/2016 12,33 12,51 11,99 12,15 -1,46% 4,22% 800.800
14/12/2016 12,33 12,57 12,05 12,33 -0,56% 4,22% 680.000
13/12/2016 12,68 12,77 12,26 12,40 -1,27% 4,02% 408.900
12/12/2016 12,75 12,91 12,50 12,56 -1,80% 3,25% 423.000
09/12/2016 12,90 13,33 12,70 12,79 -0,54% 4,88% 709.800
08/12/2016 12,04 12,96 11,75 12,86 +6,55% 10,05% 934.100
07/12/2016 12,10 12,38 11,79 12,07 -1,47% 4,88% 603.200